Distribution of the Phosphatidylinositol 3-Kinase Inhibitors Pictilisib (GDC-0941) and GNE-317 in U87 and GS2 Intracranial Glioblastoma Models—Assessment by Matrix-Assisted Laser Desorption Ionization Imaging
- 1 July 2014
- journal article
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 42 (7) , 1110-1116
Abstract
Glioblastoma multiforme (GBM) is the most common primary brain tumor in adults, and the limited available treatment options have not meaningfully impacted patient survival in the past decades. Such poor outcomes can be at least partly attributed to the inability of most drugs tested to cross the blood-brain barrier and reach all areas of the glioma. The objectives of these studies were to visualize and compare by matrix-assisted laser desorption ionization (MALDI) imaging mass spectrometry the brain and tumor distribution of the phosphatidylinositol 3-kinase (PI3K) inhibitors pictilisib (GDC-0941, 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine) and GNE-317 [5-(6-(3-methoxyoxetan-3-yl)-7-methyl-4-morpholinothieno[3,2-d]pyrimidin-2-yl)pyrimidin-2-amine] in U87 and GS2 orthotopic models of GBM, models that exhibit differing blood-brain barrier characteristics. Following administration to tumor-bearing mice, pictilisib was readily detected within tumors of the contrast-enhancing U87 model whereas it was not located in tumors of the nonenhancing GS2 model. In both GBM models, pictilisib was not detected in the healthy brain. In contrast, GNE-317 was uniformly distributed throughout the brain in the U87 and GS2 models. MALDI imaging revealed also that the pictilisib signal varied regionally by up to 6-fold within the U87 tumors whereas GNE-317 intratumor levels were more homogeneous. Liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) analyses of the nontumored half of the brain showed pictilisib had brain-to-plasma ratios lower than 0.03 whereas they were greater than 1 for GNE-317, in agreement with their brain penetration properties. These results in orthotopic models representing either the contrast-enhancing or invasive areas of GBM clearly demonstrate the need for whole-brain distribution to potentially achieve long-term efficacy in GBM.Keywords
This publication has 33 references indexed in Scilit:
- The Somatic Genomic Landscape of GlioblastomaCell, 2013
- Function of the Blood-Brain Barrier and Restriction of Drug Delivery to Invasive Glioma Cells: Findings in an Orthotopic Rat Xenograft Model of GliomaDrug Metabolism and Disposition, 2013
- Heterogeneity Maintenance in Glioblastoma: A Social NetworkCancer Research, 2011
- Delivery of molecularly targeted therapy to malignant glioma, a disease of the whole brainExpert Reviews in Molecular Medicine, 2011
- Distribution of Gefitinib to the Brain Is Limited by P-glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2)-Mediated Active EffluxThe Journal of Pharmacology and Experimental Therapeutics, 2010
- mTOR signaling in glioblastoma: lessons learned from bench to bedsideNeuro-Oncology, 2010
- U87MG Decoded: The Genomic Sequence of a Cytogenetically Aberrant Human Cancer Cell LinePLOS Genetics, 2010
- Glioblastoma multiforme: a review of where we have been and where we are goingExpert Opinion on Investigational Drugs, 2009
- Disposition of everolimus in mdr1a−/1b− mice and after a pre-treatment of lapatinib in Swiss miceBiochemical Pharmacology, 2009
- Integrating Histology and Imaging Mass SpectrometryAnalytical Chemistry, 2004